Melbourne - Telix today advises that it will release its full year results and Annual Report for the period ended 31 December 2023 on Thursday 22 February 2024.

An investor webcast and conference call will be held at 9.00am, Friday 23 February 2024 AEDT (5.00pm, Thursday 22 February 2024 EST).

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Telix's lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix ), has been approved by the U.S. Food and Drug Administration (FDA),1 by the Australian Therapeutic Goods Administration (TGA),2 and by Health Canada.3

Contact:

Ms. Kyahn Williamson

Email: kyahn.williamson@telixpharma.com

(C) 2024 Electronic News Publishing, source ENP Newswire